Sylvie Rodrigues-Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sylvie Rodrigues-Ferreira has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Clara Nahmias
INSERM U981, Department of Molecular Medicine, Gustave Roussy Cancer Center, Villejuif, France
1 shared publication - Claudio Miguel Costa-Neto
Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirao Preto, University of Sao Paulo, 14049-900 Ribeirao Preto, SP, Brazil
1 shared publication - Françoise Cormier
INSERM Unité 1016, Institut Cochin, Paris, France
1 shared publication Marina Morel
INSERM, U1016, Institut Cochin, Paris, France
1 shared publication- Rosana Inacio Reis
National Physical Laboratory, Hampton Road, Teddington TW11 0LW, UK
1 shared publication - Véronique Baud
NF-κB, Differentiation and Cancer, Université Paris Cité, Paris, France
1 shared publication
Latest Publications
- Open Access
- 6 December 2011
- Published by Wiley in International Journal of Peptides
- Vol. 2012, 1-6
A Novel Cellular Model to Study Angiotensin II AT2 Receptor Function in Breast Cancer Cells
Recent studies have highlighted the AT1 receptor as a potential therapeutic target in breast cancer, while the role of the AT2 subtype in this disease has remained largely neglected. The present study describes the generation and characterization of a new cellular model of human invasive breast cancer cells (D3H2LN-AT2) stably expressing high levels of Flag-tagged human AT2 receptor (Flag-hAT2). These cells exhibit high-affinity binding sites for AngII, and total binding can be displaced by the AT2-selective antagonist PD123319 but not by the AT1-selective antagonist losartan. Of interest, high levels of expression of luciferase and green fluorescent protein make these cells suitable for bioluminescence and fluorescence studies in vitro and in vivo. We provide here a novel tool to investigate the AT2 receptor functions in breast cancer cells, independently of AT1 receptor activation.
- 6 December 2011
- Published by Wiley in International Journal of Peptides
- Vol. 2012, 1-6
Open AccessA Novel Cellular Model to Study Angiotensin II AT2 Receptor Function in Breast Cancer Cells
Recent studies have highlighted the AT1 receptor as a potential therapeutic target in breast cancer, while the role of the AT2 subtype in this disease has remained largely neglected. The present study describes the generation and characterization of a new cellular model of human invasive breast cancer cells (D3H2LN-AT2) stably expressing high levels of Flag-tagged human AT2 receptor (Flag-hAT2). These cells exhibit high-affinity binding sites for AngII, and total binding can be displaced by the AT2-selective antagonist PD123319 but not by the AT1-selective antagonist losartan. Of interest, high levels of expression of luciferase and green fluorescent protein make these cells suitable for bioluminescence and fluorescence studies in vitro and in vivo. We provide here a novel tool to investigate the AT2 receptor functions in breast cancer cells, independently of AT1 receptor activation.